Guide for patients & caregivers

What Does a Ki-67 Result Mean on a Pathology Report?

A Ki-67 result explained: what the proliferation index percentage measures, why cut-offs for high and low vary between labs, and calm questions for your team.

By SameCase EditorialUpdated 6 min read

Prepared with AI assistance and checked against the cited sources. No independent clinician review has been completed. How we prepare articles

What does a Ki-67 result mean?

A Ki-67 result, also called the Ki-67 index, labelling index or proliferation index, is the percentage of tumour cells in a tissue sample that show the Ki-67 protein. Because Ki-67 is present in cells that are actively going through the cell cycle, a higher percentage generally means more of the cells are dividing, and a lower percentage means fewer are.

The American Cancer Society (ACS) describes the Ki-67 test as an estimate of how quickly cancer cells copy their DNA and divide. It is one of several extra tests a pathologist may do on a biopsy or surgical sample.

This guide explains what the number measures and why it is interpreted with care. It cannot tell you what your own result means. Your care team, who can see the full report, is the right source for that.

When to get help sooner

A Ki-67 number on a report is not, by itself, a reason for emergency care. If you develop new or rapidly worsening symptoms while waiting for your results appointment, contact your care team, family doctor or local urgent care service rather than waiting.

For a life-threatening emergency, such as a suspected heart attack or stroke, call your local emergency number. The NHS suggests its 111 service when you are unsure whether you need 999; check what the equivalent is where you live.

  • The US National Cancer Institute (NCI) notes that reports can appear in a patient portal before your doctor has reviewed them. If seeing a number early is worrying, it is reasonable to ask the team when it will be discussed.

How is Ki-67 measured?

Ki-67 is measured with immunohistochemistry: a stain that binds to the Ki-67 protein is applied to thin slices of the tumour, and the pathologist, sometimes helped by image-analysis software, counts how many tumour cells are stained. A review published in Cancers (2021, open access) defines the score as the percentage of positively stained cancer cells among all the cancer cells assessed.

The same review explains that Ki-67 is found in the nucleus of cells during the active phases of the cell cycle but is absent from resting cells. That is why it is used as a marker of proliferation, meaning cell growth and division.

Is a high Ki-67 bad?

In general terms, a higher Ki-67 suggests the tumour cells are dividing more often. The ACS explains that faster division means a faster-growing cancer, and that in early-stage breast cancer Ki-67 may be used to help estimate outlook or guide treatment choices.

But a high or low number is only one piece of information. Teams also look at the type of tumour, its grade and stage, receptor and other biomarker results, and your general health. A higher Ki-67 can also point to cancers that may respond to certain treatments, which is one reason it is used when planning care. Please do not read the number alone as a prediction about you; ask your team what it adds in your situation.

Why do Ki-67 cut-offs vary?

Many people search for the 'normal' Ki-67 range. There is not one. The open-access Cancers review describes guidelines as inconsistent on which cut-off points are clinically meaningful, and lists different thresholds that have been used in breast cancer research and consensus statements over the years.

The ACS breast pathology page gives one example, describing higher values as typically over 30%. Other publications have used lower or higher thresholds, and expected values differ between breast cancer subtypes. The reasons for this variation include:

  • Different cancer types: a value that is considered high in one cancer may be ordinary in another.
  • Different methods: labs may use different stains (antibodies), counting methods and software.
  • Uneven tumours: Ki-67 staining can vary across a tumour, with busier 'hot spots' and quieter areas, so the result depends on where the cells were counted.
  • Different samples: the review notes evidence that scores from a core needle biopsy can differ systematically from scores on the larger sample removed at surgery.
  • Different observers: scoring can vary between pathologists and laboratories, which is why international groups have worked on standardising the method.

Where is Ki-67 used?

Ki-67 is often discussed in breast cancer, where the ACS says it may help estimate outlook or guide treatment in early-stage disease, and notes that results can vary with the lab, the testing method and the part of the tumour tested.

It also appears in other tumours. NCI's professional summary on gastrointestinal neuroendocrine tumours lists proliferative activity, measured by the Ki-67 index, among the features used to classify these tumours. In that setting, the Ki-67 result may be part of how the grade is decided, so the same percentage can carry a different meaning than in breast cancer. Your report should state which cancer type and system apply.

How does Ki-67 relate to tumour grade?

Grade describes how abnormal the cells look under the microscope. In breast cancer, for example, one of the grading features is the mitotic count, a direct count of cells caught in the act of dividing. Ki-67 is a separate test that estimates the share of cells in the active cell cycle.

The two often point in the same direction, but they are not the same measurement, and one does not replace the other. Grade is also different from stage, which describes the size of the tumour and how far it has spread.

Questions to ask your care team

Writing these down before your appointment can help:

  • What cut-off does your lab or team use for my type of cancer, and where does my result sit?
  • Was Ki-67 measured on the biopsy, the surgical sample or both? Do the results agree?
  • How does my Ki-67 fit with my grade, stage and other test results?
  • Does this result change the treatment options you are considering, or is it background information?
  • Is any further testing, such as a gene expression test, being considered, and why?
  • Who can I contact with questions before my next appointment?

How SameCase can help you prepare

On SameCase, patients and verified doctors share de-identified cases. Seeing how others with a similar pathology report asked about their Ki-67 result, grade and next steps can help you put your own questions into words.

Other people's results cannot be compared directly with yours, because cut-offs and methods differ, and we do not diagnose or recommend treatment. Use similar cases to prepare clearer questions for your own team.

Sources and further reading

For patients & caregivers

Share your case and learn from others

Learn from doctors and other people's cases to find a way forward with your health problem. New cases are public immediately. Don't add names or identifying details.

Keep learning